Feb 10, 2022 / 04:00PM GMT
Michael Schmidt - Guggenheim Partners - Analyst
All right. Hello, and welcome. My name is Michael Schmidt. I am one of the biotech analysts at Guggenheim. And it is my great pleasure to welcome Ian Taylor, Chief Scientific Officer of Arvinas. It's a great pleasure to host you, Ian, and thanks for joining us.
Ian Taylor - Arvinas, Inc. - Chief Scientific Officer
My pleasure. Thanks for the invitation.
Questions and Answers:
Michael Schmidt - Guggenheim Partners - AnalystAll right, super. So we'll just jump in into Q&A. Ian, Arvinas has obviously been one of the key innovators in the TPD space and also the first company to advance a degrader program into clinical development. One thing that we get asked a lot is -- and now that there's more activity in this category -- how proprietary is the TPD technology, the PROTAC technology, and how high are barriers to entry as we see more and more programs emerge?
Ian Taylor - Arvinas, Inc. - Chief Scientific Officer
Yeah,
Trustpilot
